Search

Now showing items 1-6 of 6

Duration of immune protection of SARS-CoV-2 natural infection against reinfection.

Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...

Protection against the omicron variant from previous SARS-CoV-2 infection

Altarawneh, Heba N.; Chemaitelly, Hiam; Hasan, Mohammad R.; Ayoub, Houssein H.; Qassim, Suelen; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Other)

Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ...

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.

Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Hasan, Mohammad R; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...

Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 omicron infections.

Qassim, Suelen H; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53 fewer cycles (95% CI: 3.46-3.60), signifying higher infectiousness. This may reflect higher viral load and/or longer duration of ...

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

Ahmed, Zaqout; Almaslamani, Muna A.; Chemaitelly, Hiam; Hashim, Samar A.; Ittaman, Ajithkumar; ... more authors ... less authors ( Elsevier , 2022 , Article)

ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe ...

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2

Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; Coyle, Peter; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Other)

More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ...